Cequent Begins Long-Term Tox Study with FAP Drug | GenomeWeb

Cequent Pharmaceutials said this week that it has begun a long-term toxicology study of its preclinical treatment for familial adenomatous polyposis, dubbed CEQ508.

The drug, which is based on Cequent's proprietary transkingdom RNAi technology, is poised to enter phase I testing this quarter. The company said the toxicology work, which is being conducted in non-human primates, will lay the groundwork for a phase II study to begin in 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.